Anti-angiogenesis and metastasis: a tumour and stromal cell alliance
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-angiogenesis and metastasis: a tumour and stromal cell alliance
Authors
Keywords
-
Journal
JOURNAL OF INTERNAL MEDICINE
Volume 273, Issue 2, Pages 128-137
Publisher
Wiley
Online
2013-04-12
DOI
10.1111/joim.12018
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
- (2012) Farbod Shojaei et al. CANCER LETTERS
- Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer
- (2012) Lidia Moserle et al. EMBO Molecular Medicine
- Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform
- (2012) Andrea Casazza et al. EMBO Molecular Medicine
- Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice
- (2012) Federica Maione et al. JOURNAL OF CLINICAL INVESTIGATION
- Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
- (2012) Alicia S Chung et al. JOURNAL OF PATHOLOGY
- Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
- (2012) Mallika Singh et al. JOURNAL OF PATHOLOGY
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
- (2011) Peter Friedl et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect
- (2011) Ubaldo E. Martinez-Outschoorn et al. CELL CYCLE
- Is the Postprogression Survival Time Really Not Shortened in the Bevacizumab-Containing Arms of Phase III Clinical Trials?
- (2011) Piotr Potemski JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Antiangiogenic therapy, hypoxia and metastasis: risky liaisons, or not?
- (2011) Katrien De Bock et al. Nature Reviews Clinical Oncology
- Inflammation-mediated promotion of invasion and metastasis
- (2010) Graziella Solinas et al. CANCER AND METASTASIS REVIEWS
- Understanding the "lethal" drivers of tumor-stroma co-evolution
- (2010) Michael P. Lisanti et al. CANCER BIOLOGY & THERAPY
- Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe?
- (2010) Paolo Michieli CELL CYCLE
- Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis
- (2010) X. Lu et al. CLINICAL CANCER RESEARCH
- Cancer Dissemination—Lessons from Leukocytes
- (2010) Chris D. Madsen et al. DEVELOPMENTAL CELL
- Mechanisms of resistance to antiangiogenesis therapy
- (2010) Faisal Azam et al. EUROPEAN JOURNAL OF CANCER
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon
- (2009) Elizabeth R. Plimack et al. CANCER
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Endothelial Cells Form a Phalanx to Block Tumor Metastasis
- (2009) Victoria L. Bautch CELL
- Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization
- (2009) Massimiliano Mazzone et al. CELL
- Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
- (2009) Annamaria Rapisarda et al. DRUG RESISTANCE UPDATES
- Mechanisms of collective cell migration at a glance
- (2009) O. Ilina et al. JOURNAL OF CELL SCIENCE
- Anticancer strategies involving the vasculature
- (2009) Victoria L. Heath et al. Nature Reviews Clinical Oncology
- Sunitinib versus interferon-α in metastatic RCC
- (2009) Jason E. Faris et al. Nature Reviews Clinical Oncology
- Antiangiogenic therapies for high-grade glioma
- (2009) Andrew D. Norden et al. Nature Reviews Neurology
- Hypoxia Generates a More Invasive Phenotype of Tumour Cells: An In Vivo Experimental Setup Based on the Chorioallantoic Membrane
- (2009) Resit Demir et al. PATHOLOGY & ONCOLOGY RESEARCH
- The clinical implications of the genetics of renal cell carcinoma
- (2009) Inger Rosner et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- MET receptor tyrosine kinase as a therapeutic anticancer target
- (2008) Christine M. Stellrecht et al. CANCER LETTERS
- Graded hypoxia modulates the invasive potential of HT1080 fibrosarcoma and MDA MB231 carcinoma cells
- (2008) Patrick Subarsky et al. CLINICAL & EXPERIMENTAL METASTASIS
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
- (2008) R. M. Zuniga et al. JOURNAL OF NEURO-ONCOLOGY
- Angiogenesis as a strategic target for ovarian cancer therapy
- (2008) Whitney A Spannuth et al. Nature clinical practice. Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started